The VEGFA gene provides instructions for making vascular endothelial growth factor A, a protein whose primary job is building and maintaining blood vessels. It is one of the most intensely studied genes in modern medicine because it sits at the center of processes ranging from embryonic development to tumor growth to vision loss. What makes VEGFA unusual is that the same gene can produce proteins with opposite effects: some forms encourage new blood vessels to sprout, while others actively prevent it. That molecular toggle, along with the gene’s sensitivity to oxygen levels, makes VEGFA a linchpin of both normal physiology and a wide range of diseases.
What the VEGFA Gene Actually Does
At the most basic level, VEGFA tells cells to make a signaling protein that lands on the surface of blood-vessel-lining cells (endothelial cells) and instructs them to grow, divide, and form new vessels. This process, called angiogenesis, is how the body builds its circulatory network during embryonic development, repairs tissue after injury, and supports the menstrual cycle in adults. The protein also helps keep existing blood vessels healthy by promoting the survival of the cells that line them.
How critical is VEGFA? Knockout experiments in mice showed that losing even one of the two copies of the gene is lethal. Embryos missing a single VEGFA copy died between days 11 and 12 of development, with severe defects in blood vessel formation and blood-island development.1PubMed. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene Most genes can lose one copy without catastrophic consequences. The fact that VEGFA cannot tolerate even a 50% reduction in output underscores how precisely the body needs to control this protein’s levels.
One Gene, Many Proteins
The VEGFA gene contains eight exons, stretches of DNA that can be mixed and matched when the gene’s instructions are read and processed. Through a mechanism called alternative splicing, different combinations of these exons produce different versions of the VEGF-A protein. These versions, or isoforms, vary in size and in how tightly they cling to the cell surface versus diffusing freely through tissue. The most commonly discussed isoforms are named by their amino acid length: VEGF-121, VEGF-165, VEGF-189, and VEGF-206, among others. VEGF-165 is the most abundant form in most tissues.
The real twist lies in exon 8, the gene’s final coding exon. Depending on exactly where the splicing machinery cuts, the gene produces either a pro-angiogenic isoform (one that promotes vessel growth) or an anti-angiogenic isoform that actively suppresses it. The anti-angiogenic versions are designated with a “b” suffix, as in VEGF-165b. In healthy tissue, these opposing isoforms exist in a rough balance.2PubMed Central. VEGF-A splicing: the key to anti-angiogenic therapeutics? When that balance tilts toward the pro-angiogenic versions, diseases involving excessive blood vessel growth can follow. When it tilts the other way, tissues may not get the blood supply they need.
Anti-angiogenic VEGF isoforms are widely expressed in normal human tissues but tend to be downregulated in cancers, diabetic retinopathy, and several other conditions characterized by abnormal vessel growth.3PubMed Central. The anti-angiogenic isoforms of VEGF in health and disease This means the disease is not simply “too much VEGF” but rather a shift in which version of the protein the gene is making. That distinction matters for how therapies are designed, because a drug that blocks all VEGF-A indiscriminately also wipes out the protective anti-angiogenic forms.
How the Body Turns VEGFA On
The strongest natural trigger for VEGFA expression is low oxygen. When a tissue is not getting enough blood flow, cells detect the oxygen drop and stabilize a protein called HIF-1α, which under normal oxygen conditions is rapidly broken down. Once stabilized, HIF-1α moves into the cell nucleus, binds to the VEGFA gene’s promoter region, and cranks up production of VEGF-A protein.4Current Medicinal Chemistry. Critical Role of Hypoxia Sensor – HIF-1α in VEGF Gene Activation. Implications for Angiogenesis and Tissue Injury Healing The logic is elegant: tissue that is oxygen-starved sends a chemical call for new blood vessels, and VEGF-A is the main messenger carrying that call.
This oxygen-sensing mechanism explains why VEGFA is so active in wound healing (damaged tissue loses its blood supply), in growing tumors (which quickly outstrip their local circulation), and at high altitudes (where oxygen is thin). It also explains why the gene is relatively quiet in well-oxygenated adult tissues under normal circumstances.
Beyond oxygen sensing, VEGFA expression is also fine-tuned after the gene has been read into messenger RNA. A growing body of research shows that small non-coding RNA molecules, particularly microRNAs, regulate how stable that mRNA is and how efficiently it gets translated into protein. Long non-coding RNAs and circular RNAs add another layer by modulating the microRNAs that target VEGF-A mRNA.5PubMed Central. Non-coding RNA regulatory networks in post-transcriptional regulation of VEGFA in cancer These regulatory networks are especially active in cancer, where they can push VEGF-A production far above normal levels even when the HIF-1α pathway is not the main driver.
How the VEGF-A Protein Signals
Once VEGF-A is secreted, it finds its way to the surface of endothelial cells, where it binds to receptor proteins. The two main receptors are VEGFR1 and VEGFR2. VEGF-A binds to both, but VEGFR2 is the primary workhorse for the growth and survival signals that drive angiogenesis.6PubMed Central. Structural Basis for Vascular Endothelial Growth Factor Receptor Activation and Implications for Disease Therapy VEGFR1 plays a more complex role, sometimes acting as a decoy that sequesters excess VEGF-A away from VEGFR2.
VEGF-A also binds, with lower affinity, to co-receptors called neuropilins. Neuropilin-1, for example, does not signal on its own but boosts the binding affinity of VEGFR2 for the VEGF-165 isoform.7PubMed. New insights into the role of co-receptor neuropilins in tumour angiogenesis and lymphangiogenesis and targeted therapy strategies Think of neuropilins as assistants that hold the receptor and ligand together more tightly, amplifying the signal.
When VEGF-A docks on VEGFR2, the receptor pairs up with another VEGFR2 molecule and triggers a cascade of chemical signals inside the cell. One major branch activates a pathway that promotes cell survival and growth. Another branch releases calcium stores inside the cell and activates enzymes that make blood vessel walls more permeable, allowing fluid and proteins to leak through.8JCI Insight. Endothelial VEGFR2-PLCγ signaling regulates vascular permeability and antitumor immunity through eNOS/Src That permeability effect is why VEGF-A was originally called “vascular permeability factor” before researchers understood the full scope of what it does.
VEGFA in Cancer
Tumors cannot grow beyond a few millimeters in diameter without a blood supply. To solve this problem, cancer cells hijack VEGFA signaling. As a tumor mass expands, its interior becomes oxygen-starved, which activates the HIF-1α pathway described earlier and drives VEGF-A production. The secreted protein recruits nearby blood vessels to sprout branches toward the tumor, a process researchers call the “angiogenic switch.”
Experimental work in tumor models has shown just how dependent this switch is on VEGFA. Overexpressing the gene caused tumors to develop blood vessels sooner and with more complex branching, while knocking the gene out prevented the first tumor vessel from sprouting at all.9PubMed Central. The inhibition of protein translation promotes tumor angiogenic switch Without VEGFA, tumors remained small, starved, and unable to grow aggressively.
The blood vessels that tumors build under VEGF-A influence are not normal. They are irregularly shaped, tortuous, leaky, and poorly organized, lacking the clear hierarchy of arteries, veins, and capillaries found in healthy tissue.10Oncology. VEGF as a Key Mediator of Angiogenesis in Cancer This leakiness raises fluid pressure inside the tumor, which paradoxically makes it harder for chemotherapy drugs to penetrate. It also helps explain why anti-VEGF therapy sometimes improves the effectiveness of chemotherapy: by “normalizing” the chaotic tumor vasculature, it temporarily creates a window where drugs can reach cancer cells more efficiently.
VEGFA and Eye Disease
The retina is one of the most metabolically active tissues in the body, and VEGF-A plays a prominent role in retinal diseases. In diabetic retinopathy, chronic high blood sugar damages the tiny blood vessels feeding the retina, triggering a hypoxic response that ramps up VEGF-A. The protein drives new, fragile vessels to sprout across the retinal surface and causes fluid to accumulate within the retina itself, leading to diabetic macular edema and, in advanced cases, proliferative diabetic retinopathy.11PubMed Central. VEGF in Diabetic Retinopathy and Age-Related Macular Degeneration
A similar dynamic occurs in wet age-related macular degeneration, where abnormal blood vessels grow from the layer beneath the retina into the macula, leaking fluid and blood that blur central vision. The dry form of macular degeneration, by contrast, does not appear to be driven by VEGF-A.12PubMed Central. VEGF in Diabetic Retinopathy and Age-Related Macular Degeneration This distinction is clinically important because anti-VEGF injections, the primary treatment for wet macular degeneration, are not useful for the dry form.
The development of drugs injected directly into the eye to neutralize VEGF-A has been one of the great therapeutic success stories of the last two decades. Before these treatments, wet macular degeneration almost inevitably led to severe vision loss. Now, most patients can stabilize or even recover some vision with regular injections.
Anti-VEGF Drugs and Their Limits
Several anti-VEGF drugs are now in routine clinical use. Bevacizumab and ranibizumab, for instance, are antibodies (or antibody fragments) that bind directly to VEGF-A molecules, preventing them from activating their receptors. Bevacizumab was first approved for colorectal cancer and is now used in several cancer types, while ranibizumab was developed specifically for eye diseases. Both work by latching onto VEGF-A and blocking its receptor-binding sites.
Other anti-VEGF agents take different approaches. Some block the VEGF receptor itself rather than the ligand. Still others, like aflibercept, act as decoy receptors: they mimic the VEGF receptor closely enough to trap VEGF-A before it reaches real receptors on endothelial cells.
These drugs can be remarkably effective, but they come with a well-recognized set of side effects. Because VEGF-A is essential for maintaining healthy blood vessels throughout the body, systemic anti-VEGF therapy can cause high blood pressure, protein in the urine, kidney dysfunction, and in some cases kidney failure or a condition called thrombotic microangiopathy, where small blood vessels become damaged and clots form.13American Journal of Physiology-Renal Physiology. Mechanisms of anti-VEGF therapy-induced kidney injury: current insights and future perspectives in combination with immune checkpoint inhibitors Kidney damage can force dose reductions or treatment interruptions in cancer patients, limiting the drug’s usefulness. The mechanisms behind these kidney effects are still not fully understood, which complicates efforts to prevent them.
Resistance is another major challenge. Tumors that initially respond to anti-VEGF therapy often find workarounds, activating alternative pro-angiogenic pathways that do not depend on VEGF-A. The tumor essentially reroutes its blood supply using different molecular signals, rendering the anti-VEGF drug ineffective over time. Researchers have cataloged multiple such escape routes, but reliably blocking all of them simultaneously remains an unsolved problem.
Genetic Variation in VEGFA and Disease Risk
People carry naturally occurring variations, or polymorphisms, in and around the VEGFA gene. Some of these influence how much VEGF-A protein an individual produces, which in turn can affect susceptibility to diseases driven by angiogenesis. For example, certain VEGFA genotypes have been linked to higher risk of diffuse large B-cell lymphoma, a type of blood cancer. One study found that carrying the VEGFA -1154GG genotype was associated with about a 1.6-fold increase in lymphoma risk, and specific combinations of VEGFA and VEGF-receptor variants raised the risk further, up to roughly twofold.14PubMed. Association of single nucleotide variants in VEGFA and KDR with the risk and angiogenic features of diffuse large B-cell lymphoma
Other VEGFA polymorphisms have been studied in the context of solid tumors, diabetic complications, preeclampsia, and cardiovascular disease. The general pattern is that variants associated with higher VEGF-A expression tend to correlate with greater angiogenic activity in tumors and sometimes worse clinical outcomes. However, these are population-level statistical associations, not diagnostic certainties. Carrying a particular VEGFA variant does not mean you will develop a specific disease; it shifts the odds modestly in one direction.
Roles Beyond Blood Vessels
For years, researchers assumed VEGF-A was primarily a vascular molecule. That view has changed substantially. Studies have shown that VEGF-A also acts directly on neurons, promoting their survival and the growth of their projections, independently of any effect on blood vessels.15PubMed Central. VEGF in the nervous system VEGF-A encourages the birth of new neurons, supports the patterning of neural circuits during development, and protects existing neurons from damage.
These findings have implications for neurodegenerative disease research. If VEGF-A helps keep neurons alive and functioning, then chronically low VEGF-A signaling might contribute to conditions involving neuronal loss. Conversely, anti-VEGF therapies used in cancer and eye disease could theoretically have unintended effects on the nervous system, although clinically significant neurological side effects from current anti-VEGF drugs appear to be rare. The nervous-system roles of VEGF-A are still an active area of investigation, and much of what researchers know comes from cell culture and animal models rather than large human studies.
An Ancient Gene
VEGF-A is not unique to mammals, or even to vertebrates. Researchers have identified VEGF-like molecules and their receptors in fruit flies, roundworms, and even jellyfish. In these simple organisms, VEGF-related proteins function in developmental cell migration and the growth of neural structures rather than blood vessel formation, since many of these animals lack a circulatory system entirely.16PubMed Central. The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease The existence of VEGF signaling in organisms without blood vessels suggests that the gene family first evolved to guide cells during development and was later co-opted for vascular purposes as circulatory systems became more complex.
This evolutionary history helps explain why VEGF-A does so many things in mammals. Its ancestral functions in cell migration and neural development were never lost; new vascular functions were simply layered on top. The result is a single gene product that participates in an unusually wide array of biological processes, which is partly why blocking it therapeutically always involves tradeoffs.
Using Synthetic VEGF-A mRNA as a Therapy
While most therapeutic attention has focused on blocking VEGF-A, there is a parallel effort to deliver it. In patients with heart disease, parts of the heart muscle may be alive but chronically short of blood. The idea behind VEGF-A mRNA therapy is straightforward: inject synthetic mRNA encoding VEGF-A directly into oxygen-starved heart tissue, prompting cells to temporarily produce the protein and stimulate local blood vessel growth.
A clinical trial called EPICCURE has tested this approach in patients undergoing coronary artery bypass surgery. The drug, designated AZD8601, is a modified VEGF-A165 mRNA formulated in a simple saline buffer rather than a lipid nanoparticle, designed to produce a burst of VEGF-A protein at the injection site with minimal immune reaction. Injections are delivered directly into regions of the heart muscle identified by imaging as viable but underperfused.17Molecular Therapy – Methods & Clinical Development. Synthetic mRNA Encoding VEGF-A in Patients Undergoing Coronary Artery Bypass Grafting: Design of a Phase 2a Clinical Trial The approach is still in early-stage testing, but it represents a conceptually different use of VEGFA knowledge: instead of dampening the gene’s effects, clinicians are trying to harness them in a controlled, localized way.
If the strategy proves safe and effective, it could open the door to mRNA-based therapies for other conditions involving inadequate blood supply, such as peripheral artery disease or chronic wounds that refuse to heal. The challenge is precision. VEGF-A production needs to be high enough to seed new vessels but temporary enough that it does not trigger runaway growth or the leaky, abnormal vasculature seen in tumors. Getting that dosing window right is the central problem these trials are designed to solve.